Viewing Study NCT00546793


Ignite Creation Date: 2025-12-25 @ 12:56 AM
Ignite Modification Date: 2026-03-02 @ 10:04 PM
Study NCT ID: NCT00546793
Status: COMPLETED
Last Update Posted: 2021-08-16
First Post: 2007-10-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Sponsor: Gilead Sciences
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module